Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05003986 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Study acronym: EPPIK
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 47 sitesv28
  2. Study sites: 46 to 47v27
  3. Site details revised at 3 of 46 sitesv26
  4. Primary completion date: May 1, 2025 to Mar 12, 2027
    • Study completion date: Jun 1, 2025 to Apr 12, 2027
    • Study description expanded, about 1 word
    v25
  5. Site details revised at 1 of 46 sitesv24
Show 22 earlier versionsHide 22 earlier versions
  1. Site details revised at 4 of 46 sitesv23
  2. Study sites: 42 to 46v22
  3. Enrollment target: 57 to 67v21 Show 6 more changesShow less
    • Study sites: 41 to 42
    • Interventions: Sparsentan (Drug), Sparsentan (Drug) to Sparsentan (Drug), Sparsentan (Drug), Sparsentan (Drug)
    • Eligibility criteria expanded, about 79 words
    • Secondary endpoints: 8 to 9
    • Study description expanded, about 64 words
    • Study arms: 2 to 3
  4. Study sites: 38 to 41v20
  5. Study sites: 35 to 38v19
  6. Study sites: 33 to 35v18
  7. Site details revised at 2 of 33 sitesv17
  8. Study sites: 32 to 33v16
  9. Study sites: 29 to 32v15
  10. Study sites: 26 to 29v14
  11. Eligibility criteria expanded, about 34 words
    • Secondary endpoints: 7 to 8
    • Study description expanded, about 74 words
    v13
  12. Study sites: 25 to 26v12
  13. Study sites: 24 to 25v11
  14. Study sites: 23 to 24v10
  15. Re-verified, no change to tracked fieldsv9
  16. Study sites: 18 to 23v8
  17. Study sites: 11 to 18v7
  18. Study sites: 6 to 11v6
  19. Study sites: 5 to 6v5
  20. Study sites: 3 to 5v4
  21. Site details revised at 1 of 3 sitesv3
  22. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 3
    • Start date changed from estimate of Aug 31, 2021 to Aug 12, 2021
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Trial Details
NCT Number NCT05003986
Lead Sponsor Travere Therapeutics, Inc.
Conditions
(from sponsor)		 Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Related terms Glomerulonephritis, IGA, Glomerulosclerosis, Focal Segmental, IgA Vasculitis, Macular dystrophy, corneal type 1, Nephritis, Hereditary, Nephrosis, Lipoid
Enrollment 67 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov